Newron Pharmaceuticals S.p.A.

XETRA NP5.DE

Newron Pharmaceuticals S.p.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -211.92 K

Newron Pharmaceuticals S.p.A. Net Cash Used Provided By Financing Activities is USD -211.92 K for the year ending December 31, 2023, a -6.49% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Newron Pharmaceuticals S.p.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -199.01 K, a -101.18% change year over year.
  • Newron Pharmaceuticals S.p.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 16.88 M, a 87.65% change year over year.
  • Newron Pharmaceuticals S.p.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 9.00 M, a -54.37% change year over year.
  • Newron Pharmaceuticals S.p.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 19.72 M, a 33,683.14% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
XETRA: NP5.DE

Newron Pharmaceuticals S.p.A.

CEO Mr. Stefan Weber
IPO Date July 4, 2019
Location Italy
Headquarters via Ludovico Ariosto 21
Employees 22
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

StockViz Staff

February 6, 2025

Any question? Send us an email